Abstract:
The study was a prospective, randomized, single-blind clinical experiment that was conducted from June 2021 to June 2022. A total of 142 patients with reduced ejection fraction and chronic heart failure were randomly select- ed. Each patient received treatment with either spirono- lactone (Spiron-HF group). Results: In individuals with reduced ejection fraction and chronic heart failure, epler- enone has a positive effect on cardiac remodeling param- eters (left ventricular ejection fraction and left ventricular systolic size, volume, and diameter). In patients with re- duced ejection fraction and chronic heart failure, taking eplerenone, statistically significant reduction in all-cause and cardiovascular mortality was observed compared with those taking spironolactone. Conclusions: The cru- cial role of plerenone in the treatment of patients with reduced ejection fraction and chronic heart failure is con- firmed by its ability to effectively block mineralocorticoid receptors, minimize side effects and significantly reduce the risk of hospitalization and cardiovascular mortality.
